HUTCHMED (China) Limited (NASDAQ:HCM – Get Rating) shares gapped up prior to trading on Wednesday . The stock had previously closed at $10.05, but opened at $10.65. HUTCHMED shares last traded at $10.38, with a volume of 410 shares trading hands.
Wall Street Analyst Weigh In
A number of research firms recently issued reports on HCM. StockNews.com began coverage on HUTCHMED in a research note on Wednesday, October 12th. They set a “hold” rating on the stock. The Goldman Sachs Group boosted their price objective on HUTCHMED from $14.00 to $16.00 and gave the company a “neutral” rating in a research note on Tuesday, August 9th.
HUTCHMED Stock Performance
The business has a 50 day moving average of $9.31 and a 200-day moving average of $11.09.
Hedge Funds Weigh In On HUTCHMED
HUTCHMED Company Profile
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors.
- Get a free copy of the StockNews.com research report on HUTCHMED (HCM)
- Microsoft Shares: Is it Time to Back Up the Truck?
- Is the 60/40 Portfolio Mix Still in Vogue?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Three CBD Stocks to Dominate a Budding Industry
- Institutional Support for Analog Devices Remains High
Receive News & Ratings for HUTCHMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHMED and related companies with MarketBeat.com's FREE daily email newsletter.